|
Daclizumab HYP verhoogt kans op ziektevrije status bij RRMS
Care 4 Cure (abonnement) Een post-hoc analyse van de SELECT-studie laten zien dat bij behandeling met daclizumab high-yield process (DAC HYP) meer RRMS-patiënten ziektevrij zijn dan met placebo: 39% (n=156) versus 11% (n=22). Dit komt overeen met een odds ratio (OR) van … |
|
Biogen covers all bases for personalised approach to MS
PharmaTimes Data is also being presented on Biogen’s investigational MS drugs, such as Plegridy (pegylated interferon beta-1a), the pegylated version of its older blockbuster Avonex and daclizumab, a once-monthly subcutaneous injection being developed with AbbVie. |
|
3 Stocks to Buy When Your Government Shuts Down
DailyFinance Biogen continues to invest in multiple sclerosis, with a late-stage study under way for daclizumab and regulatory filings already submitted for Plegridy. However, Biogen’s pipeline holds promise in other areas as well. It awaits approval for drugs that … |
|
3 Stocks to Buy When Your Government Shuts Down
Motley Fool Biogen continues to invest in multiple sclerosis, with a late-stage study under way for daclizumab and regulatory filings already submitted for Plegridy. However, Biogen’s pipeline holds promise in other areas as well. It awaits approval for drugs that … |
|
Biogen Idec presentará nuevos datos ampliados de su sólida cartera de …
Lainformacion.com PROCESO DE ALTO RENDIMIENTO DE DACLIZUMAB (DAC HYP): está siendo desarrollado como una inyección para administrar una vez al mes. Se considera que DAC HYP se dirige a las células inmunológicas activadas que pueden desempeñar un … |
Biogen Idec to present new drug data at ECTRIMS 2013Zenopa… including information on both approved and investigational products. The firm will share the latest clinical findings on established therapies such as Tysabri, Tecfidera and Fampyra, as well…
Teleborsa |
Biogen Idec presenterà all’ECTRIMS numerosi nuovi dati relativi alla suo ampia …
Teleborsa PROCESSO DACLIZUMAB AD ELEVATO RENDIMENTO (DAC HYP): in fase di sviluppo come iniezione sottocutanea da somministrare mensilmente. Si ritiene che DAC HYP abbia come target le cellule immunitarie attive che possono giocare un ruolo … |
|
Biogen Idec présentera de nouvelles données approfondies de son portefeuille …
BFMTV.COM PROCESSUS À HAUT RENDEMENT DU DACLIZUMAB (DAC HYP – DACLIZUMAB HIGH-YIELD PROCESS) : une thérapie d’injection sous-cutanée mensuelle en cours d’élaboration. Le DAC HYP semble cibler les cellules immunitaires activées qui peuvent … |
Biogen Idec to Present Extensive New Data from Its Robust Multiple Sclerosis …Financial PostDACLIZUMAB HIGH-YIELD PROCESS (DAC HYP): is being developed as a once-monthly subcutaneous injection. DAC HYP is believed to target the activated immune cells…
|
Biogen Idec stellt umfangreiche neue Daten zu seinem robusten Portfolio für …
Finanzen.net DACLIZUMAB HIGH-YIELD PROCESS (DAC HYP): Dieser Wirkstoff wird als einmal monatlich verabreichte subkutane Injektion entwickelt. Es wird angenommen, dass DAC HYP auf die aktivierten Immunzellen abzielt, die eine sehr wichtige Rolle bei MS … |